Guidelines Panel Meeting: Localized Prostate Cancer (2021)

August 24, 2021 to November 1, 2021

This Guideline panel meeting will provide clinicians with evidence- and consensus-based principles and strategies for the diagnosis and management of localized prostate cancer based on the current state of both clinical practice and the medical literature. This panel was formed in response to the need to include new diagnostic and management options for such patients to allow urologists to determine the best approach for managing this disease.

Target Audience


Learning Objectives

After completing this activity, learners will be able to:

  1. Analyze the latest scientific evidence for diagnosis and management of localized prostate cancer.
  2. Recommend appropriate diagnostic and treatment options for localized prostate cancer.
  3. Apply improved critical thinking skills to medial literature reviews.
Course summary
Available credit: 
  • 10.00 AMA PRA Category 1 Credit™
  • 10.00 Non-Physician Participation
Course opens: 
Course expires: 
Event starts: 
08/24/2021 - 6:00pm EDT
Event ends: 
11/01/2021 - 8:00pm EDT


Day 1: August 24, 2021

6:00-6:10pm       Guidelines Stages Overview                                                                        Erin Kirkby

                              Review of Statement Development                                                        

6:10-7:00pm       Evidence Report Overview                                                                           Dr. Roger Chou


Day 2: August 30, 2021

6:00-6:10pm       Conflict of Interest Disclosures and Panel Responsibilities              Erin Kirkby


6:10-9:50pm       Evidence Report Discussion/Statement Development                      Panel

      • Review of Risk Stratification
      • General Disease Management
        • Watchful Waiting/Active Surveillance
        • Androgen Deprivation Therapy
        • Focal Therapies
        • Whole Gland Therapies
        • Combination Therapy

9:50-10:00pm     Recap and Next Steps                                                                                    Erin Kirkby


Day 3: October 10, 2021

12:00-3:50pm     Evidence Report Discussion/Statement Development                      Panel

      • Evaluation
      • Focused Treatment Review
        • Prostatectomy
        • Lymphadenectomy
        • Radiation Therapy
        • Combination Therapy
      • Follow-Up/Ongoing Management

3:50-4:00pm       Recap and Next Steps                                                                               Erin Kirkby


Day 4: November 1, 2021

6:00-7:50pm       Review of Draft Statements/Algorithm Development                      Panel

7:50-8:00pm      Recap and Next Steps                                                                              Erin Kirkby

AUA Localized Prostate Cancer Guidelines Panel Members

James A. Eastham, MDChair
Stephen A. Boorjian, MDVice-Chair
Phillip M. Pierorazio, MDPGC Representative
Tony CrispinoPatient Advocate
Gregory B. Auffenberg, MDMember
Daniel Ari Barocas, MDMember
John Warren Davis, MDMember
Scott E. Eggener, MDMember
Eric Horwitz, MDMember
Christopher J. Kane, MDMember
Daniel Wei Lin, MDMember
Sean McBride, MDMember
Alicia Morgans, MD, MPHMember
George Rodrigues, MD, PHDMember
William Wong, MDMember

PDF icon Guideline Panel Disclosures


Accreditation: The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation: The American Urological Association designates this live activity for a maximum of 10.0 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Other Learners: The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.

Evidence Based Content: It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.

AUA Disclosure Policy: All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider any relevant financial relationships with any commercial interest. The AUA must determine if the individual’s relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.

Mitigation of Identified Conflict of Interest: All disclosures will be reviewed by the AUA Conflict of Interest (COI) Review Work Group Chair and/or Vice Chair for identification of conflicts of interest. The AUA COI Review Work Group, working with Office of Education staff, will document the mechanism(s) for management and mitigation of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to mitigate conflict of interest:

  • Peer review for valid, evidence-based content by the AUA COI Review Work Group.
  • Limit content to evidence with no recommendations
  • Introduction of a debate format with an unbiased moderator (point-counterpoint)
  • Inclusion of moderated panel discussion
  • Publication of a parallel or rebuttal article for an article that is felt to be biased
  • Limit equipment representatives to providing logistics and operation support only in procedural demonstrations
  • Divestiture of the relationship by faculty
  • Selection of alternative faculty for specific topic

Off-label or Unapproved Use of Drugs or Devices: The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.


Disclaimer: The opinions and recommendations expressed by faculty, authors and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the AUA.

Consent to Use of Photographic Images: Attendance at or participation in AUA meetings and other activities constitutes an agreement by the registrant to AUA's use and distribution (both now and in the future) of the attendee's image or voice in photographs and electronic reproductions of such meetings and activities.

Audio, Video and Photographic Equipment: The use of audio, video and other photographic recording equipment by attendees is prohibited inside AUA meeting rooms.

Reproduction Permission: Reproduction of written materials developed for this AUA course is prohibited without the written permission from individual authors and the American Urological Association.

Special Assistance/Dietary Needs: The AUA complies with the Americans with Disabilities Act §12112(a). If any participant is in need of special assistance or has any dietary restrictions, please see the registration desk.

Available Credit

  • 10.00 AMA PRA Category 1 Credit™
  • 10.00 Non-Physician Participation
Please login or register to take this course.

Attendees, please click "Take Course" to complete the evaluation, claim credit and print certificate.